PubMed · 2005 · 121 citations · 17 references
MedicinePharmacokineticsPharmacologyDrug MetabolismPain ManagementPharmacodynamicsAnalgesiaAnalgesic PharmacologyOpioid AnalgesicsOpioid PharmacologyOpioid TherapyOpioid TitrationAnalgesic EffectsAnalgesic TitrationCancer Pain Opioid TherapyCancer Pain PharmacotherapyExtended-release Opioid FormulationsOpioid Analgesic ManagementOpioid ConversionOpioid Dose Conversion
Methadone is a synthetic opioid with potent analgesic effects, commonly used for cancer and chronic neuropathic pain, and its unique pharmacokinetics make it a valuable alternative when dose escalation of other opioids is limited by side effects, though individual metabolism varies and requires slow titration with close monitoring. Conversion to methadone should be based on the patient’s current daily oral morphine equivalent dosage. Methadone therapy can delay the onset of systemic toxicity for several days after initiation or dose escalation, and it is also less expensive than other sustained‑release opioid formulations.
Methadone is a synthetic opioid with potent analgesic effects. Although it is associated commonly with the treatment of opioid addiction, it may be prescribed by licensed family physicians for analgesia. Methadone's unique pharmacokinetics and pharmacodynamics make it a valuable option in the management of cancer pain and other chronic pain, including neuropathic pain states. It may be an appropriate replacement for opioids when side effects have limited further dosage escalation. Metabolism of and response to methadone varies with each patient. Transition to methadone and dosage titration should be completed slowly and with frequent monitoring. Conversion should be based on the current daily oral morphine equivalent dosage. After starting methadone therapy or increasing the dosage, systemic toxicity may not become apparent for several days. Some medications alter the absorption or metabolism of methadone, and their concurrent use may require dosing adjustments. Methadone is less expensive than other sustained-release opioid formulations.
17
The use of methadone in cancer pain poorly responsive to other opioids
J. S. Morley, Matthew Makin · Pain Reviews · 1998 · 131 citations